Taro Pharmaceutical Industries, a subsidiary of Sun Pharmaceutical Industries, has recalled more than 17,000 units of an antifungal product in the United States following manufacturing-related concerns, according to the US Food and Drug Administration (USFDA).
In its latest enforcement report, the US health regulator said that Taro is recalling 17,664 units of Ciclopirox Shampoo, a medication commonly used to treat seborrheic dermatitis, a skin condition characterised by dryness, flaking and itching. The recalled product was manufactured at the company’s Hawthorne facility.
The USFDA noted that the recall was initiated due to a failure to meet impurity and degradation specifications. Taro began the nationwide Class II recall on December 9, 2025.
Under USFDA guidelines, a Class II recall is issued when the use of a product may cause temporary or medically reversible adverse health effects, or when the probability of serious health consequences is considered low.
Taro Pharmaceutical Industries was merged with Sun Pharmaceutical Industries last year in a transaction valued at $347.73 million, following which Taro became a privately held entity wholly owned by Sun Pharma. Sun Pharma has held a controlling stake in Taro since 2010.
Taro primarily operates in the dermatology segment and manufactures a wide range of prescription as well as over-the-counter pharmaceutical products.
